Table S4.
Distribution of BF/non-BF EC-caused BSI in cancer patients
| Tumor type | BF-EC (81) | non-BF-EC (243) | P-value |
|---|---|---|---|
|
| |||
| Hematological malignancies | 9 (11.11) | 10 (4.12) | 0.020 |
| Lung cancer | 5 (6.17) | 21 (8.64) | 0.479 |
| Mammary cancer | 9 (11.1) | 16 (6.58) | 0.187 |
| Gynecological cancera | 6 (7.41) | 27 (11.11) | 0.341 |
| Colorectal cancer | 17 (20.99) | 28 (11.52) | 0.033 |
| Pancreatic cancer | 10 (12.35) | 51(20.99) | 0.085 |
| Hepatic carcinoma | 14 (17.28) | 35 (14.40) | 0.532 |
| Gastric carcinoma | 8 (9.88) | 35 (14.40) | 0.299 |
| Bladder cancer | 3 (3.70) | 7 (2.88) | 0.711 |
| Prostate cancer | 0 | 6 (2.47) | 0.154 |
| Renal carcinoma | 0 | 2 (2.1) | 0.413 |
| Othersb | 0 | 5 (2.06) | 0.194 |
Notes:
a
Includes cervical cancer, endometrial carcinoma, ovarian cancer.
b
Includes melanoma, buccal cancer, glioma, meningioma.
Abbreviations: BF, biofilm formation; BSI, bloodstream infection; EC, Escherichia coli.